{"id":"daprodustat-large","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3544988","moleculeType":"Small molecule","molecularWeight":"393.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting prolyl hydroxylase enzymes, daprodustat prevents the degradation of hypoxia-inducible factor (HIF), allowing HIF to accumulate and activate genes involved in erythropoietin (EPO) synthesis. This leads to increased red blood cell production without requiring exogenous EPO administration. The mechanism mimics the body's natural response to hypoxia, potentially offering advantages over traditional ESA (erythropoiesis-stimulating agent) therapies.","oneSentence":"Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:34.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease in patients on dialysis"},{"name":"Anemia of chronic kidney disease in non-dialysis patients"}]},"trialDetails":[{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Daprodustat large","genericName":"Daprodustat large","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation. Used for Anemia of chronic kidney disease in patients on dialysis, Anemia of chronic kidney disease in non-dialysis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}